Heartburn in primary care: Problems below the surface

Journal of Gastroenterology

Volumn 39, Issue 11, 2004, Pages 1027-1034

  Holtmann, Gerald ^a,b   Maldonado Lopez, Evelyn ^a   Haag, Sebastian ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Gastroesophageal reflux disease (GERD); Heartburn; Primary care; Quality of life (QoL)

Indexed keywords

ALCOHOL; ANTACID AGENT; CAFFEINE; CYCLOSPORIN; DIAZEPAM; DICLOFENAC; DIGOXIN; ESOMEPRAZOLE; GLIBENCLAMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOPROLOL; NAPROXEN; NIFEDIPINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PHENAZONE; PHENPROCOUMON; PHENYTOIN; PIROXICAM; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS; THEOPHYLLINE; WARFARIN;

BARRETT ESOPHAGUS; BRADYCARDIA; CANCER RISK; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EROSION; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; KIDNEY FAILURE; LIFESTYLE; LONG TERM CARE; NEUROPATHY; PREDICTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; STOMACH ACID; STOMACH ACID SECRETION; SYMPTOMATOLOGY;

ANTACIDS; ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; LIFE STYLE; PRIMARY HEALTH CARE; PROTON PUMPS; QUALITY OF LIFE; RECURRENCE; RISK FACTORS;

EID: 10244220012     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1440-8     Document Type: Review

References (44)

1. Jones RH, Hungin AP, Philipps J, Mills JG. Gastro-oesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-54.
2. Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1995;211(Suppl):35-8.
3. Shaw SA, Adlis S, Beebe TJ, Talley NJ, Kane RI. When does simple heartburn become a disease (abstract)? Gastroenterology 1998;114:A284.
4. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
5. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999;231(Suppl):48-54.
6. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq; 1984. p. 170-83.
7. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993; 199(Suppl 28):18-21.
8. Ollyo J-B, Monnier P, Fontolliet C, Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993;3(Suppl):3-10.
9. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.
10. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
11. Cohen S, Parkman HP. Heartburn - a serious symptom. N Engl J Med 1999;340:878-9.
12. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:1016-22.
13. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-24.
14. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastrooesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
15. Smout AJ. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997;11(Suppl 2):81-5.
16. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther 1999;13:117-27.
17. Vicari JJ, Peek RM, Falk GW, Goldblum JR, Easley KA, Schnell J, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.
18. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000;95:387-94.
19. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112:1442-7.
20. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastrooesophageal reflux disease in general practice. BMJ 2001; 322:344-7.
21. Dent J. Management of reflux disease. Gut 2002;50(Suppl 4):67-71.
22. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-810.
23. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003;63:101-32.
24. Scholten T, Gatz G, Sander P. Pantoprazole 40mg (Panto) relieves primary reflux symptoms more rapidly than omeprazole MUPS 20mg (Ome) in patients with severe GERD symptomatology (abstract). Gastroenterology 2000;118(Suppl 2):A1303.
25. Kromer W, Horbach S, Lühmann R. Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis. Pharmacology 1999;59:57-77.
26. Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, et al. GERD 2003-a consensus on the way ahead. Digestion 2003;67:111-17.
27. Simon B, Mueller P, Pascu O, Gatz G, Sander P, Huber R, et al. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: A crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003;15:791-9.
28. Gillessen A, Bei IW, Modlin IM. 40 mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from GERD-related symptoms. J Clin Gastroenterol 2004;38:332-40.
29. Koerner T, Schuetze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis: Results of a multinational study. Digestion 2003;67:6-13.
30. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Ailment Pharmacol Ther 2003;18:587-94.
31. Bardhan KD, van Rensburg CJ. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1585-91.
32. Moss SF, Arnold R, Tytgat GNJ, Spechler SJ, Delle Fave G, Rosin D, et al. Consensus statement for management of gastroesophageal reflux disease. J Clin Gastroenterol 1998;27:6-12.
33. Lauritsen K, Jaup BH, Carling L, Raptis S, Aadland E, Farkkila M, et al. Comparable efficacy of pantoprazole and omeprazole to prevent relapse in patients with GERD (abstract). Gut 2000; 47(Suppl 3):A60.
34. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-6.
35. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
36. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-3.
37. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-4.
38. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:395-407.
39. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
40. Meyer US. Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions. Yale J Biol Med 1996;69:203-9.
41. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:523-37.
42. Radhofer-Welte X. Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. Drugs Today (Barc) 1999;35:765-72.
43. McLaughlin TP, Yazdani C, Okamoto LJ, Tedeschi M. Concomitant use of proton pump inhibitors and metabolically competing drugs and the risk of drug drug interaction-induced adverse events (abstract). Gastroenterology 2001;120(Suppl 1):A2061.
44. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001;285:2331-8